-
ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen
At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…
-
ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…
-
ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…
-
ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…
-
ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL
To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…
-
TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer
At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…
-
Professor Yige Bao: Perioperative Vidicitamab Plus Immunotherapy Enables Kidney-Sparing Treatment in High-Risk UTUC
Editor’s note: Upper tract urothelial carcinoma (UTUC) accounts for about 17.9% of all urothelial carcinomas (UC) in China. For high-risk UTUC, radical nephroureterectomy (RNU) is the standard surgical procedure, but…
-
NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?
Editor’s note: The incidence of genitourinary cancers in China has continued to rise, with prostate, bladder, and kidney cancers ranking among the most common malignancies. Among them, eosinophilic renal tumors…
Connecting Medical Expertise through Media